Change‐point joint model for identification of plateau of activity in early phase trials
Author:
Affiliation:
1. Early drug analytics ‐ Translational Clinical Oncology Novartis Pharma AG Rueil‐Malmaison France
2. Université Versailles St Quentin, Université Paris Saclay, INSERM U900 STAMPM Saint‐Cloud France
3. Institut Curie Paris France
Publisher
Wiley
Subject
Statistics and Probability,Epidemiology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.8889
Reference43 articles.
1. The changing landscape of phase I trials in oncology
2. Design considerations for early-phase clinical trials of immune-oncology agents
3. Dose-finding designs for cumulative toxicities using multiple constraints
4. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose
5. Drug development in oncology: classical cytotoxics and molecularly targeted agents
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors;Statistics in Medicine;2024-06-10
2. CRM and partial order CRM with adaptive rescaling for dose‐finding in immunotherapy trials with a continuous outcome;Statistics in Medicine;2023-04-03
3. Change‐point joint model for identification of plateau of activity in early phase trials;Statistics in Medicine;2021-02-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3